SNY - Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline Highlights 12 Blockbuster Opportunities | Benzinga
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbuster potential (to make over $1 billion in annual sales), including nine medicines and vaccines, each with €2 billion-€5 billion in peak sales potential.
The company also highlighted three "pipeline-in-a-product" assets with a potential of more than €5 billion in peak sales.
CEO Paul Hudson is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.
The French drugmaker said it expected its recently launched and future pharmaceutical assets to generate more than €10 billion of annual ...